Elsevier

The Lancet Oncology

Volume 7, Issue 9, September 2006, Pages 778-780
The Lancet Oncology

Case Report
Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab

https://doi.org/10.1016/S1470-2045(06)70864-6Get rights and content

First page preview

First page preview
Click to open first page preview

References (10)

There are more references available in the full text version of this article.

Cited by (79)

  • Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression

    2020, Cancer Treatment Reviews
    Citation Excerpt :

    Data regarding tumor grade were provided only in eight cases (grade 1: 12.5%, grade 2: 50%, grade 3: 37.5%) [21,22,24,32,34,35,38]. The tumor was estrogen-receptor positive in 15 cases [19,22–24,26,27,29,33,34,38] and progesterone-receptor positive in 11 cases [19,22–24,26,34,38]. All patients had a confirmed HER2-positive status in the primary tumor.

  • Leptomeningeal carcinomatosis in patients with breast cancer

    2019, Critical Reviews in Oncology/Hematology
  • Management of central nervous system metastases in breast cancer

    2018, The Breast: Comprehensive Management of Benign and Malignant Diseases
  • Leptomeningeal metastasis

    2018, Handbook of Clinical Neurology
  • Brain Metastases from Breast Cancer in Patients Receiving Trastuzumab

    2016, Brain Metastases from Primary Tumors: Epidemiology, Biology, and Therapy of Melanoma and Other Cancers
  • Neoplastic Meningitis

    2016, Handbook of Neuro-Oncology Neuroimaging: Second Edition
View all citing articles on Scopus
View full text